Efficacy and Safety of Bevacizumab-Containing Chemotherapy Regimens in Metastatic Breast Cancer


Efficacy and Safety of Bevacizumab-Containing Chemotherapy Regimens in Metastatic Breast Cancer
Slides from presentations at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

Nasim S et al. A meta-analysis of risk of cardiovascular events in patients with metastatic breast cancer (MBC) treated with anti vascular endothelial growth factor (VEGF) therapy — Bevacizumab. San Antonio Breast Cancer Symposium 2010;Abstract P6-12-01.

Schwartzberg LS et al. Phase II multicenter study of docetaxel and bevacizumab +/- trastuzumab as first-line treatment of patients with metastatic breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract P6-12-08.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.